The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery

European Journal of Nuclear Medicine

Volumn 27, Issue 4, 2000, Pages 431-440

  Rubello, Domenico ^a   Mazzarotto, Renzo ^a   Casara, Dario ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Differentiated thyroid carcinoma; Follow up; Metastatic disease; Technetium 99m methoxyisobutylisonitrile; Therapy planning

Indexed keywords

IODINE 131; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; AGED; ARTICLE; CANCER RISK; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE PERIOD; PROGNOSIS; SCINTIGRAPHY; THYROID CARCINOMA; THYROIDECTOMY;

EID: 0033999121     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050527     Document Type: Article

References (26)

1. 1. Yen TC, Lin HD, Lee CH, Chang SL, Yeh SH. The role of technetium-99m sestamibi whole body scans in diagnosis metastatic Hürthle cell carcinoma of the thyroid gland after total thyroidectomy: a comparison with iodine-131 and thallium-201. Eur J Nucl Med 1994; 21: 980-983.
2. 2. Nemec J, Nyvltova O, Blazek T, Vicek P, Racek P, Novak Z, Preningerova M, Hubilckova M, Krizova M, Zimak J, Bilek R. Positive thyroid cancer scintigraphy using technetium-99m methoxyisobutylisonitrile. Eur J Nucl Med 1996; 23: 69-71.
3. 3. Dietlein M, Sceihauer K, Voth E, Thessen P, Schica H. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm? Nuklearmedizin 1998; 37: 12-17.
4. 99mTc-MIBI for recurrent and metastatic differentiated thyroid carcinoma. Nuklearmedizin 1997; 36: 7-12.
5. 131I in patients with metastatic thyroid carcinoma. Nucl Med Commun 1997; 18: 3-9.
6. 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 1997; 7: 327-335.
7. 7. Miyamoto S, Kasagi K, Misaki T, Alam MS, Konishi J. Evaluation of technetium-99m-MIBI scintigraphy in metastatic differentiated thyroid carcinoma. J Nucl Med 1997; 38: 352-356.
8. 99mTc-MIBI SPECT in the metastatic lesions of thyroid cancer. Nippon Igaku Hoshasen Gakkai Zasshi 1997; 57: 127-132.
9. 9. Ugur O, Kostakoglu L, Caner B, Uysal U, Elahi N, Nalilghi M, Yuksel D, Aras T, Bekdik C. Comparison of Tl-201, Tc-99m-MIBI and I-131 imaging in the follow-up of patients with well differentiated thyroid carcinoma. Nucl Med Commun 1996; 17: 373-377.
10. 131I scan. Thyroidol Clin Exp 1997; 9: 95-100.
11. 99mTc MIBI scan combined with high resolution neck ultrasonography. Tumori 1999; 85: 120-125.
12. 12. Casara D, Rubello D, Saladini G, Gallo V, Masarotto G, Busnardo B. Distant metastases in differentiated thyroid cancer: long-term results of radioiodine treatment and statistical analysis of prognostic factors. Tumori 1991; 77: 432-436.
13. 13. Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Gireli ME, Busnardo B. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993; 34: 1626-1631.
14. 14. Rubello D, Girelli ME, Casara D, Piccolo M, Perin A, Busnardo B. Usefulness of combined antithyroglobulin antibodies and thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest 1990; 13: 737-742.
15. 15. Rubello D, Casara D, Girelli ME, Piccolo M, Busnardo B. Clinical meaning of anti-thyroglobulin antibodies in differentiated thyroid cancer: a prospective study. J Nucl Med 1991; 33: 1478-1480.
16. 16. Mazzaferri E, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-428.
17. 17. Beierwaltes WH. The treatment of thyroid carcinoma with radioactive iodine. Semin Nucl Med 1978; 8: 79-94.
18. 18. Aiello DP, Manni A. Thyroglobulin measurement vs iodine 131 total-body scan for the follow-up of well-differentiated thyroid cancer. Arch Intern Med 1990; 150: 437-439.
19. 19. Grigsby PW, Baglan K, Siegel BA. Surveillance of patients to detect recurrent thyroid carcinoma. Cancer 1999; 85: 945-951.
20. 20. Franceschi M, Kusic Z, Franceschi D, Luiniac L, Roncevic S. Thyroglobulin determination, neck ultrasonography and iodine-131 whole body scintigraphy in differentiated thyroid carcinoma. J Nucl Med 1996; 37: 446-451.
21. 21. Sutton RT, Reading CC, Charboneau JW, James EM, Grant CS, Hay ID. US-guided biopsy of the neck masses in postoperative management of patients with thyroid cancer. Radiology 1988; 168: 769-774.
22. 22. DeGroot LJ, Kaplan EL, McCormik M, Strauss F. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990; 71: 414-424.
23. 23. Hay ID, Bergstrahl EJ, Goellner JR, Ebersold JR. Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114: 1050-1058.
24. 24. Thoresen SO, Akslen LA, Glattre E, Haldorsen T, Lund EV, Schoultz M. Survival and prognostic factors in differentiated thyroid cancer. A multivariate analysis of 1055 cases. Br J Cancer 1989; 59: 231-235.
25. 25. Noguchi S, Yamashita H, Murakami N, Nakayama I, Toda M, Kawamoto H. Small carcinomas of the thyroid. A long term follow-up of 867 patients. Arch Surg 1996; 131: 187-191.
26. 26. Girelli ME, Busnardo B, Amerio R, Casara D, Betterle C, Piccolo M. Critical evaluation of serum thyroglobulin (Tg) levels during thyroid hormone suppression therapy versus Tg levels after hormone withdrawal and total body scan: results in 291 patients with thyroid cancer. Eur J Nucl Med 1986; 11: 333-335.